Insulet’s modeled fair value has been trimmed from US$369.64 to US$354.40, signaling a more measured view of upside in the current setup. That shift lines up with Street research that is resetting ...

Insulet Corporation (NASDAQ:PODD) is among the 10 High Growth S&P 500 Stocks to Buy Now. Truist on February 19, 2026, lowered ...

Insulet Stock: why GLP-1 fears are overblown, with growth driven by Europe/MENA expansion. Read here for a detailed analysis on PODD stock.

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...

Fintel reports that on May 7, 2024, Wolfe Research upgraded their outlook for Insulet (NasdaqGS:PODD) from Peer Perform to Outperform. As of May 2, 2024, the average one-year price target for Insulet ...

Its Q4 revenue jumped ~29% YoY on a constant currency basis to $783.8M, exceeding the consensus by $15.1M, as its revenue ...

Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption of ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Wednesday morning. Here’s what to ...